[Oral dyskinesia in rats after a single administration of haloperidol combined with GABA-linoleamide. A model of dyskinesia in man].
Wistar male rats received haloperidol (0.6 mg.kg-1, i.p.) and GABA-linoleamide (10 mg.kg-1, i.p.) and have been observed 120 or 240 minutes after administrations, during 2 minutes, in order to quantify oral dyskinesias (vacuous chewing movements, teeth chattering & grating) and catalepsy. It has been observed a significant potentiation of catalepsy with apparition of oral dyskinesias, in comparison with rats receiving only haloperidol. This phenomenon, probably due to the inhibition of the striato-nigral GABA-ergic pathway, could serve as an easy and reliable model for the human tardive dyskinesias dues to the chronic administration of neuroleptics. It could be complementary or be used in place of the actual models on rats and monkeys, which need neuroleptic administration during several months. Moreover oral dyskinesias, obtained with haloperidol and GABA-linoleamide, provide an additional argument on the role of the striato-nigral GABA-ergic pathway's failure in the pathogenesis of human tardive dyskinesias. Specific compensation of this failure could constitute a new therapeutic approach for tardive dyskinesias.
Vamvakides
A
A
D000818:Animals; D002375:Catalepsy / Q000139:chemically induced; D004195:Disease Models, Animal; D004357:Drug Synergism; D004409:Dyskinesia, Drug-Induced; D006220:Haloperidol; D008297:Male; D009059:Mouth Diseases / Q000139:chemically induced*; D011619:Psychotropic Drugs; D051381:Rats; D011919:Rats, Inbred Strains; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives*
D011619:Psychotropic Drugs; D005680:gamma-Aminobutyric Acid; C036611:gabalid; D006220:Haloperidol
Dyskinésies orales chez le rat après administration unique d'halopéridol associé au GABA-linoléamide. Un modèle des dyskinésies chez l'homme.